- Published at
- by gurufocus.com
mixed
mixed
News for Verastem, Inc. (VSTM)
- Published at
- by seekingalpha.com
positivepositiveVerastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination (NASDAQ:VSTM)
Verastem, Inc.'s priority PDUFA date for avutometinib + defactinib in LGSOC set for June 2025; explore future data updates. Click for my VSTM stock update.- Published at
- by gurufocus.com
positivepositiveVerastem (VSTM): Jefferies Initiates Coverage with Buy Rating Amid FDA Review
Jefferies initiates coverage on Verastem (VSTM) with a- Published at
- by benzinga.com
positivepositiveThis Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Ligand Pharmaceuticals (NASDAQ:LGND), MannKind (NASDAQ:MNKD)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...- Published at
- by gurufocus.com
positivepositiveVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock- Published at
- by zacks.com
neutralneutralWall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.- Published at
- by gurufocus.com
mixedmixedVerastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results f- Published at
- by benzinga.com
mixedmixedHallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Akebia Therapeutics (NASDAQ:AKBA), Arlo Technologies (NYSE:ARLO)
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Hallador Energy Company HNRG fell sharply in today's...- Published at
- by benzinga.com
mixedmixedWhy Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - AirNet Technology (NASDAQ:ANTE), AGM Gr Hldgs (NASDAQ:AGMH)
Shares of Harrow, Inc. HROW rose sharply in pre-market trading after the company reported fourth quarter and year-end 2024 unaudited preliminary financial resul...- Published at
- by seekingalpha.com
positivepositiveVerastem: Upcoming PDUFA, But I Remain Cautious (NASDAQ:VSTM)
Verastem's assets, Avutometinib and Defactinib, show promising results in treating KRAS-mutated LGSOC. Read why VSTM stock is a Hold.- Published at
- by gurufocus.com
mixedmixedWhy the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
PR NewswireVANCOUVER, BC, March 8, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 8, 2025 /PRNewswire/- Published at
- by gurufocus.com
positivepositiveNantahala Capital Management, LLC Increases Stake in Verastem Inc
Nantahala Capital Management, LLC (Trades, Portfolio), a prominent investment firm, executed a significant stock transaction on December 31, 2024. The firm adde- Published at
- by gurufocus.com
positivepositiveBIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition of Verastem Inc Shares
On December 31, 2024, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio) executed a significant transaction by acquiring an additional 427,030 shares of Verastem- Published at
- by gurufocus.com
mixedmixedAlyeska Investment Group Reduces Stake in Verastem Inc
Significant Transaction by Alyeska Investment Group On December 31, 2024, Alyeska Investment Group, L.P. (Trades, Portfolio) executed a notable transaction invo- Published at
- by gurufocus.com
positivepositiveBarclays PLC's Strategic Acquisition of Verastem Inc Shares
On December 31, 2024, Barclays PLC executed a significant transaction by acquiring 3,894,093 shares of Verastem Inc (VSTM) at a price of $5.17 per share. This s- Published at
- by gurufocus.com
positivepositiveBalyasny Asset Management L.P. Acquires Significant Stake in Verastem Inc
Introduction to the Transaction On December 31, 2024, Balyasny Asset Management L.P. (Trades, Portfolio) executed a noteworthy transaction by acquiring 3,945,92- Published at
- by gurufocus.com
mixedmixedVanguard Group Inc. Increases Stake in Verastem Inc.
On December 31, 2024, Vanguard Group Inc. made a significant move by acquiring an additional 382,816 shares of Verastem Inc. at a price of $5.17 per share. This- Published at
- by rttnews.com
neutralneutralVerastem Oncology Appoints Matthew Ros As COO, Stock Up In Pre-Market
Verastem Inc. (VSTM), doing business as Verastem Oncology, Wednesday announced the appointment of Matthew Ros as chief operating officer. Previously, Ros had served as chief executive officer and board director at FORE Biotherapeutics, an oncology company.- Published at
- by gurufocus.com
mixedmixedVerastem Oncology Names Matthew E. Ros as Chief Operating Officer
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today ann- Published at
- by seekingalpha.com
neutralneutralVerastem: Planning The PDUFA Run-Up (NASDAQ:VSTM)
Verastem, Inc.'s promising therapy for LGSOC could position them as a commercial-stage company by 2025, capturing a big market share. Click for my VSTM update.